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bstract
Methotrexate (MTX) is a cytostatic agent widely used in combination with other agents as adjuvant chemotherapy for breast cancer and is
ssociated with cognitive impairment as a long-term side effect in some cancer patients. This paper aimed to identify a neurobiological mechanism
ossibly responsible for this cognitive impairment using an animal model.
The first study explored the hypothesis that MTX reduces neuronal cell proliferation. A dose-dependent long-lasting decrease in hippocampal cell
roliferation was shown with Ki-67 immunocytochemistry, following a single intravenous injection of MTX (37.5–300 mg/kg). Animals treated
ith MTX also showed a dose-dependent transient decrease in body weight gain.
In the second study, the effect of MTX (250 mg/kg) on two spatial learning tasks was examined. Animals treated with MTX learned the Morris
ater maze task adequately; however, these animals showed a longer latency time to cross the platform location in the probe trial, reflecting an
mpairment of spatial memory function. In the novel object recognition task, animals treated with MTX failed to distinguish a novel object from a
amiliar one, indicating a decrease in the comparator function of the hippocampus.Our studies indicated that, in the rat, MTX has a dose-dependent negative effect on hippocampal cell proliferation, and on cognitive behavior.
hese findings suggest that adverse effects of certain cytotoxic agents on hippocampal cell proliferation may have a potential contributory role in
ognitive impairment observed in humans after chemotherapy.
2007 Elsevier B.V. All rights reserved.
icity
and neurophysiological studies, cognitive impairment is consis-
tently observed in a subgroup of patients treated with variouseywords: Methotrexate; Neurogenesis; Cognitive impairment; Rat; Neurotox
. IntroductionCytostatic drugs are often applied in modern oncology;
atients live longer and even survive. Hence, increasing attention
s paid to negative side effects. In several neuropsychological
∗ Corresponding author. Tel.: +31 50 3632345; fax: +31 50 3632331.
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oi:10.1016/j.bbr.2007.08.004egimens of adjuvant chemotherapy for breast cancer (CMF1,
1 CMF regimen: cyclophosphamide, 100 mg/m2 orally on days 1–14;
ethotrexate 40 mg/m2 intravenously on days 1 and 8; 5-fluorouracil 600 mg/m2
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TC2, FEC3) [1,7,9,25,34–36,38,42,43]. These deficits range
rom very subtle to more severe and are observed in a wide range
f brain functions, including memory, concentration, and speed
f information processing [25], and can be noticed up to 10 years
fter completion of cytotoxic treatment [1]. Recently, a clinical
tudy was performed in which the effect of CMF chemother-
py on grey and white matter volume was examined. People
ho had received adjuvant chemotherapy showed smaller grey
nd white matter volume in the prefrontal and parahippocam-
al gyrus 1 year after treatment, compared to those who had
ot received chemotherapy. These findings were significantly
orrelated with impairments in attention, concentration and/or
isual memory. Effects of chemotherapy on brain volume were
ot noticed 3 years after treatment [21].
Despite these indications of negative effects on the central
ervous system resulting in persistent cognitive dysfunction, our
nderstanding of the nature of the cognitive impairment and
he underlying mechanisms is fragmentary at best. Due to the
ompound nature of the chemotherapeutic regimens, in humans
t is difficult to isolate specific etiological agents responsible for
he cognitive impairment observed. Animal models of human
ognitive function might help elucidate the neural mechanisms
ediating cytostatic brain damage.
In the few animal studies performed, mainly methotrexate
MTX), a frequently used cytotoxic agent in the clinic, was
xamined. Philips et al. showed that, after high-dose adminis-
ration of MTX into the femoral vein in rats, several behavioral
hanges occurred including reduced spontaneous activity and
iminished startle response to loud noise or vibrissal stimula-
ion [30]. Another study investigating high-dose intraperitoneal
njections of MTX showed enhanced occurrence of seizures in
ice (possibly due to a lowering of GABA content), and an
mpairment of long-term memory in a passive avoidance task
40].
A potential mechanism underlying the adverse effect on brain
unctioning but not yet studied, is the effect of cytostatic drugs
n neurogenesis. In the 1960s it was established that the pro-
uction of new cells in the adult brain is not restricted to glial
ells, but there is also a persistent production of neurons [3].
his neurogenesis has recently received much attention. Studies
ave shown that stem cells continuously produce new neurons
n several brain areas, the most prominent ones being the sub-
entricular zone (SVZ), which lines the lateral ventricles, and
he sub granular zone (SGZ) of the hippocampal dentate gyrus
DG) [17,24]. Since the hippocampal formation is well known
or its involvement in learning and memory processes, it is sug-
ested that neurogenesis in this brain structure plays a functional
ole in cognitive performance. Animals with lowered neurogen-
sis perform worse in hippocampal-dependent tasks and exhibit
learning impairment [17], whereas an enriched environment
2 CTC regimen: cyclophosphamide, 6 g/m2 intravenously; thiotepa,
80 mg/m2 intravenously; carboplatin, 1.6 g/m2 intravenously; divided over 4
ays.
3 FEC regimen: 5-fluorouracil, 500 mg/m2 intravenously; epidoxorubicin,
0–120 mg/m2 intravenously; cyclophosphamide, 500 mg/m2 intravenously;
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nhances neurogenesis, and increases learning capacity [23,28].
ince many cytotoxic compounds, like MTX, are aimed at the
nhibition of the process of cell division, they will probably also
ffect cell proliferation in the brain if they are able to pass the
lood–brain barrier. Although it is assumed that most cytotoxic
gents do not pass the blood–brain barrier, MTX seems to be
n exception [12]. Therefore, we hypothesize that due to MTX,
ippocampal cell proliferation is negatively affected, which may
lay a contributory role in the cognitive decline observed in some
ancer patients.
We tested this hypothesis in two different studies. The first
tudy determined the dose–response relationship between MTX
nd hippocampal cell proliferation. Since Ki-67 is a nuclear pro-
ein antigen involved in cell proliferation regulation [33], Ki-67
ositive cells were immunocytochemically visualized and quan-
ified in the SGZ by light microscopic analysis of brain sections
weeks after administration of the cytostatic drug.
The second study explored the effects of a high-dose MTX
n cognitive performance in hippocampal-dependent learning
asks. Three weeks after treatment with MTX, animals were
rained in the Morris water maze (MWM). Another group of
nimals was subjected to the novel object recognition (NOR)
ask, performed 4 weeks after treatment with MTX.
. Methods
.1. General
Adult (3 months of age) male Wistar rats (Harlan, Zeist, The Netherlands,
verage bodyweight at the start of the experiment 297.1 g ± 11.67 S.E.M.)
ere housed individually in clear Plexiglas cages (25 cm × 25 cm × 30 cm) on
layer of wood shavings with a fixed 12:12 h light:dark cycle with lights on at
8.00 a.m., and food and water ad libitum.
Experiments started 2 weeks after arrival of the animals according to the
rotocol described below. After injection with MTX (100 mg/ml, Pharmachemie
V, Haarlem, The Netherlands), animals received intraperitoneal injections of
alcium leucovorin (10 mg/ml, Pharmachemie BV, Haarlem, The Netherlands),
hich is clinically used as a so-called rescue therapy in combination with the
ytotoxic agent. Tetrahydrofolate (THFA) is a cofactor in DNA synthesis, MTX
s an inhibitor of the enzyme THFA reductase and depletes the pool of tetrahy-
rofolates. Leucovorin is a tetrahydrofolate and does not require activation by
HFA reductase [16,20]. The rescue therapy of leucovorin was administered in
protocol similar to that applied in patients. Eighteen hours after the injection
f MTX, leucovorin was administered in a concentration that was 8% of the
njected MTX dosage; at 26, 42, and 50 h the administered concentration was
educed to 4%. Pilot studies showed that leucovorin itself does not have an effect
n neurogenesis and that high-dose MTX without leucovorin is lethal, due to
evere diarrhea and weight loss.
All experiments were approved by the Animal Experimentation Committee
f the University of Groningen.
.2. MTX dose–response interaction for body weight gain and
ippocampal cell proliferation
In the first study, rats were injected with various dosages of MTX (37.5, 75,
50 or 300 mg/kg) in the tail vein under a short-lasting (<3 min) mild O2-N2O-
soflurane anesthesia. Control animals were injected with saline. Body weight of
ll animals was measured on a daily basis. The animals were sacrificed 3 weeks
fter the injection through transcardial perfusion with saline followed by 4%
araformaldehyde. Brains were removed and placed in 30% sucrose solution at
◦C. Microtome sections of the hippocampus (40m) were stored in 0.01 M


















































































in body weight gain between the different treatments was sig-
nificant, F4,60 = 3.057, P < 0.0001. The difference between the
control animals and the animals treated with 37.5 and 75 mg/kg
MTX was significant with P < 0.05. The difference between the
Fig. 1. Body weight gain after intravenous administration of saline (©) or MTX
(() 37.5 mg/kg; () 75 mg/kg; () 150 mg/kg; () 300 mg/kg;n = 6 per group).
Body weight before the injection (given on day 0) is expressed as 100%, bars70 R. Seigers et al. / Behavioural B
From the serial sections, every twelfth section from each animal was selected
nd immunocytochemically stained for Ki-67 using a slightly adapted stan-
ard protocol [22]. In brief, free-floating sections were pre-treated with 0.4%
2O2 for 30 min, to stop endogenous peroxidase activity. Non-specific bind-
ng of immunoreagents was blocked with 3% normal goat serum (Zymed, San
rancisco, USA). Subsequently, sections were incubated with mouse-anti-Ki-67
1:200, Novocastra, Newcastle upon Tyne, UK), for 48 h at 4 ◦C. After a second
locking step, sections were incubated with a biotinylated secondary antibody
1:400, goat-anti-mouse, Jackson, Wet Grove, PA, USA) for 2 h at room tem-
erature. This was followed by incubation in an avidin biotinylated peroxidase
omplex (1:400, ABC Elite Kit, Vector Laboratories, Burlingame, CA, USA).
abeled cells were visualized with 0.15 mg/ml diaminobenzidine (DAB) and
.003% H2O2 solution.
After mounting of the sections onto glass slides for microscopic analysis,
ections were counterstained with a Mayer-haematox solution for 30 s. Counting
f Ki-67 positive cells in both hemispheres of the dentate gyrus was performed
nder a light microscope with a magnification of 400×. Counting was performed
n the subgranular layer of the dentate gyrus. Counts in both blades were summed.
he borders of the area that was quantified was defined as the subgranular
ayer having a thickness of two cell diameters. All cells were counted in the
ubgranular layer of the dentate gyrus from top to bottom of the 40m thick
ection. Because every twelfth section of the brain was stained, the amount of
ositive cells was multiplied by 12 to get the estimated total amount of Ki-67
ositive cells in the hippocampus.
.3. Effects of high-dosage MTX on cognitive performance
In patients, MTX, in the dosage used as adjuvant chemotherapy in the CMF
ocktail, induces a body weight loss of approximately 10% and mild diarrhea
13]. In order to achieve similar effects in animals and based on the effects of
he dose–response interaction, we injected rats with 250 mg/kg MTX for the
ehavioral tasks, which were performed after the animals recovered from the
ickness caused by MTX.
.3.1. Morris water maze learning
Animals were injected with either saline or MTX (250 mg/kg) as previ-
usly described. Three weeks after treatment, the MWM task was performed,
hich tests spatial cognitive performance. The task was performed in a circular
lack pool (∅ 140 cm) with a black platform. The pool was filled with water of
6 ± 1 ◦C, so that the platform was about 1 cm below the water surface. The pool
as surrounded with external, constant cues and the observer always sat in the
ame position. The task consisted of five training days with two trials per day
ith an inter-trial time of 1 h. One trial lasted for 3 min or until the rat found the
latform and sat on it for 10 s. If a rat did not find the platform within 3 min, it
as guided by hand. On day 6, the platform was removed and the rat was placed
n the pool for a probe trial which lasted 1 min. Behavior of the animal was
racked by using Ethovision 3.0 and analyzed for escape latency in the learning
hase, meaning the time from the beginning of the trial until the rat sat on the
latform. During the probe trial, the time spent before the animal crossed the
latform location was recorded.
.3.2. Novel object recognition
Animals received an injection of either saline or MTX (250 mg/kg) as
reviously described. Four weeks after treatment, the comparator function of
he hippocampus was tested in a NOR task. The task was performed in a
ooden box (40 cm × 50 cm × 80 cm) without bedding. The animals received
habituation session on day 1 to explore the box without objects, lasting
min. Day 2 consisted of two trials, each lasting 3 min, with an inter trial
ime of 1 h. In the first trial, the acquisition phase, two identical objects
Duplo Lego toys, cubes, 6.5 cm × 6.5 cm × 7 cm) were placed in the center
f the box, 13 cm apart. In the second trial, the recollection phase, one object
as replaced by a novel object, with a different shape and color (rectangle,
cm × 13 cm × 8 cm). Objects were securely fixed to the floor of the box using
ape, so the animals could not move them around. The objects and the box
ere cleaned after each session with 70% alcohol. Exploration behavior of the
ifferent objects (sniffing or touching the objects), was analyzed using Eline
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xploring the novel object divided by the time spent exploring the familiar
bject.
.4. Statistics
Body weight was analyzed using repeated measure ANOVA. Light-
icroscopic counts of Ki-67 positive cells and the behavioral tasks were
nalyzed using one-way ANOVA with treatment as between-subject variable.
SD post-hoc test was performed when the ANOVA test was significant. For
ll statistical tests, a probability value less than 0.05 was considered to be
tatistically significant.
. Results
.1. MTX dose–response interaction for body weight and
ippocampal cell proliferation
.1.1. Body weight gain
Body weight gain was calculated as absolute body
eight/absolute body weight on the day of the injection, mul-
iplied by 100. For day 0 (the day of the injection), this
ill give a relative body weight of 100%; body weight gain
s determined as the relative body weight that is more than
00%.
All rats showed a decrease in body weight gain after the
njection (Fig. 1). Whereas the control animals and animals that
eceived 37.5 mg/kg MTX regained their body weight on day 2,
he other animals (75, 150 and 300 mg/kg MTX) continued to
ose weight and suffered from mild diarrhea. After day 4, all ani-
als recovered and started to regain body weight. The differenceepresent standard error of the mean. The difference in body weight gain between
he different treatments was significant,F4,60 = 3.057,P < 0.0001. The difference
etween the control animals and the animals treated with 37.5 and 75 mg/kg
TX is significant withP < 0.05. The difference between the control animals and
he animals treated with 150 and 300 mg/kg MTX is significant with P < 0.0001.





































Fig. 3. The mean escape latency in the Morris water maze test for control animals
(©) and animals treated with MTX (() 250 mg/kg; n = 8 per group). The two
trials per day are shown as average values with standard error of the mean. Con-
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ontrol animals and the animals treated with 150 and 300 mg/kg
TX was also significant with P < 0.0001.
.1.2. Ki-67 immunocytochemistry
Ki-67 positive cells in microtome sections of the hippocam-
us were visualized and counted. The average number of
ections counted per animal per group was 11.75 ± 1.23 S.E.M.,
2.00 ± 0.42 S.E.M., 11.81 ± 0.41 S.E.M., 11.13 ± 0.68
.E.M., and 12.90 ± 0.62 S.E.M. for the control animals and
he animals treated with 37.5, 75, 150, and 300 mg/kg MTX,
espectively.
The number of Ki-67 positive cells differed significantly
etween the groups, F4,23 = 6.822, P = 0.0009 (Fig. 2). Control
nimals had significantly more Ki-67 positive cells in the hip-
ocampus than animals treated with 37.5, 75 (both P < 0.005),
50 (P < 0.001) or 300 mg/kg (P < 0.0001). Two other groups,
7.5 and 75 mg/kg MTX, differ significantly from 300 mg/kg
TX (P < 0.05).
.2. Effects of high-dosage MTX on cognitive performance
.2.1. Morris water maze learning
Three weeks after injection of 250 mg/kg MTX, a MWM task
as performed. Fig. 3 shows the daily average escape latency
uring the training period. All animals learned the location of
he platform, with no significant differences between the groups.
ontrol animals and animals treated with MTX both signifi-
antly improved during the learning phase, with F4,30 = 3.135,
< 0.05; F4,40 = 4.508, P < 0.05 respectively. However, animalsreated with MTX showed a longer latency time to cross the plat-
orm area during the probe trial compared to control animals,
1,12 = 3.135, P < 0.05 for both one-way ANOVA and post-hoc
est (Fig. 4).
ig. 2. Total number of Ki-67 positive cells in the hippocampus of control rats
open bar) and animals treated with MTX (solid bar 37.5 mg/kg; diagonal striped
ar 75 mg/kg; vertical striped bar 150 mg/kg; horizontal striped bar 300 mg/kg;
= 6 per group). Data are represented as mean with standard error of the mean.
he number of Ki-67 positive cells differ significantly between the groups,
4,23 = 6.822,P = 0.0009. Control animals have significantly more Ki-67 positive
ells than animals treated with MTX (*P < 0.05; **P < 0.001; ***P < 0.0001).
wo other groups, 37.5 and 75 mg/kg MTX, differ significantly from 300 mg/kg












learning phase, with F4,30 = 3.135, P < 0.05; F4,40 = 4.508, P < 0.05 respectively.
o significant effects are seen between control animals and animals treated with
TX.
There was no difference in average swim speed or distance
raveled between control animals and animals treated with MTX
data not shown).
.2.2. Novel object recognition
Four weeks after treatment with 250 mg/kg MTX, a NOR
ask was performed. Fig. 5 shows the discrimination index (time
pent exploring the novel object/time spent exploring the famil-
ar object × 100) for the recollection phase. A discrimination
ndex of more than 100% means that the animals spent more
ime exploring the novel object than the familiar one. Control
nimals spent significantly more time exploring the novel object
han the familiar one (P < 0.05), whereas animals treated withTX spent an equal amount of time investigating both objects
Fig. 5). There was no difference in average total exploration
ime for the acquisition and recollection phase for both groups,
nd there was also no difference in average total exploration time
ig. 4. Latency time to cross the platform location in the probe trial in the Morris
ater maze test (n = 8 per group). Data are represented as mean with standard
rror of the mean. Animals treated with MTX (() 250 mg/kg) show a longer
atency time than control animals (), P < 0.05.
172 R. Seigers et al. / Behavioural Brain
Fig. 5. Discrimination index in the novel object recognition task (n = 8 per
group). The time spent exploring the novel object is expressed as percentage






















































































trror of the mean. Control animals () spent more time exploring the novel
bject than the familiar one (P < 0.05), whereas animals treated with MTX (()
50 mg/kg) spent an equal amount of time exploring both objects.
etween the control animals and the animals treated with MTX
data not shown).
. Discussion
This study investigated the long-lasting effects of methotrex-
te (MTX) on hippocampal cell proliferation and cognitive
ehavior in rats. A distinct effect was seen on hippocampal cell
roliferation in a dose-dependent manner 3 weeks after an intra-
enous injection of MTX. This was consistent with previous
ndings in our lab (unpublished data). Cytostatics, such as MTX,
re designed to interfere with the process of cell division; there-
ore, the inhibition of hippocampal cell proliferation could be
nticipated. The formation of new neurons out of stem cells in the
entate gyrus of hippocampus (neurogenesis) is thought to play
n important role in learning and memory processes [11]. Studies
ave shown that aging [5], or stress [17] has a negative effect on
eurogenesis and cognition, whereas an enriched environment
23], or running wheel activity [29] increases neurogenesis and
ognitive performance.
In our study, the lowest dosage given to the animals
37.5 mg/kg) already resulted in a significant decrease in cell
roliferation. This finding is of particular interest, since it is
uggested that MTX does not pass the blood–brain barrier
hen administered in a dosage equivalent to the one used in
he adjuvant regimen of chemotherapy for breast cancer [6].
ur findings may indicate that even a low dosage is able to
ass the blood–brain barrier in rats, or that other factors play
role in the observed neurotoxicity in the current study. One
f these factors may be the sickness that is observed in ani-
als treated with MTX, although immunocytochemistry was
erformed after the animals recovered. All dosages used in this
tudy induced sickness approximately 3 days after treatment,
hich was expressed in a decrease in body weight gain, fluffy
ur, bad general appearance, and mild diarrhea. The effects are
imilar to the clinic, where patients treated with MTX also suffer
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tudies in our laboratory indicate that directly after treatment
ith MTX body temperature slightly increased (suggesting a
ild fever) although this observation failed to reach signif-
cance (unpublished data). Whether sickness itself can have
ong-lasting effects on hippocampal cell proliferation will be
xplored in a future study.
Dietrich et al. examined the effect of carmustine (BCNU)
nd cisplatin (two other frequently used cytotoxic agents) on
ultured brain cells and found that the agents were more toxic
o progenitor cells of the CNS and non-dividing oligodendro-
ytes than for multiple cancer cell lines. The effect of these
ytotoxic agents on cell death and cell division was also studied
n mice. Three intraperitoneal injections of BCNU significantly
ncreased cell death for up to 10 days after treatment in the
orpus callosum and the hippocampal dentate gyrus, and up to
weeks in the subventricular zone. Similar effects were seen
fter 3 intraperitoneal injections of cisplatin. BCNU also sig-
ificantly decreased cell division up to 6 weeks after treatment
n the subventricular zone, the corpus callosum, and in the hip-
ocampal dentate gyrus. Cisplatin showed similar effects, but the
umber of dividing cells returned to normal levels in the sub-
entricular zone and the dentate gyrus 6 weeks after treatment
10].
In breast cancer patients, CMF chemotherapy is associated
ith cognitive decline. This decline is mostly noticed 2–6 years
fter treatment [25,34], but can be noticed as early as 3 months
fter CMF chemotherapy [44]. The decline is observed in a
ide range of brain functions, including memory, concentration,
nd speed of information processing. Of the cytotoxic agents
hat are represented in the CMF regimen, MTX is thought to
e the agent most responsible for this cognitive impairment
25]. Since we showed that MTX induces a profound and long-
asting decline in hippocampal cell proliferation (which likely
eflects an inhibition of the process of neurogenesis) we hypoth-
sized that this decline in cell proliferation could also play a
ole in the cognitive impairment observed in cancer patients
fter CMF treatment. To test this hypothesis, we performed two
ippocampal-dependent learning and memory tasks (MWM and
he NOR task), after treatment with MTX. In a recent paper Ahles
nd Saykin reported that the most affected cognitive functions
fter treatment with chemotherapy are, amongst others, episodic,
isual and spatial memory [2], which can be tested in a MWM
nd a NOR task.
In the MWM task, animals were trained to learn where a hid-
en platform was located allowing an escape from the water.
oth control and treated animals learned the task adequately.
owever, the animals treated with MTX showed a longer latency
ime to cross the platform location in the probe trial, reflecting
n impairment of spatial memory function. There was also a
endency for these animals to spend less time in the right quad-
ant compared to the control animals; however, this observation
ailed to reach significance (data not shown). In the NOR task,
he animals treated with MTX failed to distinguish a novel object
rom a familiar one, indicating a decrease in the comparator
unction of the hippocampus. Cell proliferation in the olfac-
ory bulb was also affected in the animals treated with MTX
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mell and the ability to make a distinction between the differ-
nt objects. Since the objects in our test were made of the same
aterial and cleaned after each session, it was not possible for
he animals to recognize an object by smell. The hippocampal
ependency of NOR task can be debated, however, Forwood et
l. describe that when an NOR is performed with spatial cues
resent, which was the case in our study, the task becomes more
ippocampal-dependent [14]. Furthermore, Gould et al. show
hat hippocampal lesions impair NOR memory performance in
ats, when a 1 h delay was used between training and testing
18], a protocol that we also applied in our study.
The impairment in hippocampal-dependent tasks is in line
ith a number of studies. Madhyastha et al. found a learn-
ng and memory impairment, but no anxiolytic effects in the
wo-compartment conditioned avoidance task after multiple
ntracerebroventricular injections of MTX in Wistar rats [27].
ieklucka-Dziuba et al. reported an impairment of long-term
emory in the passive avoidance task 14 days after a single
osage of MTX injected intraperitoneal in Albino Swiss mice
40]. Moreover, Yanovksi et al. showed in Lewis-inbred rat pups
mpaired learning of environmental events in a conditioned emo-
ional response task and conditioned taste aversion task after a
ingle neonatal intraperitoneal MTX injection [46]. Shors et al.
reated male Sprague–Dawley rats with the anti-mitotic MAM
or 14 days and found a distinct decrease in BrdU positive cells
n the dentate gyrus. This decrease, however, did not affect per-
ormance in the MWM or in the contextual fear conditioning,
ut did affect performance in the trace fear conditioning [39].
inocur et al. treated BALB/C mice with a combination of MTX
nd 5-fluorouracil. Drug-treated mice showed impaired learning
n a MWM, in a non-matching-to-sample test (NMTS), and in
delayed-NMTS of non-spatial memory, compared to control
nimals [45]. Since the latter tests are not hippocampal depen-
ent, it is possible that the hippocampus is not the only brain
rea responsible for the cognitive decline seen in patients after
reatment with chemotherapy. Other brain areas might also be
nvolved, for example the volume of grey and white matter as
escribed by Inagaki et al. [21].
Not all literature points to a learning impairment after
hemotherapy. Lee et al. found that female Fischer-344 rats
reated with cyclophosphamide or 5-fluorouracil (both com-
only used cytostatics) learned to find the location of a platform
n the MWM task even faster than control animals 7 weeks
fter recovery from the chemotherapy treatment; 29 weeks after
he treatment, significant effects were no longer found between
reated animals and controls [26]. In that study, animals received
ve intraperitoneal injections every 4 weeks, for a total of
8 weeks. The authors attribute the unexpected improvement
f cognitive function to the fact that cytostatics lower estro-
en production. Reduced plasma estradiol in rats is associated
ith improved learning in the MWM [19]; this is supported by
imonte-Nelson et al. [4]. In humans, chemotherapy may lead
o premature menopause [15,42], which reduces estrogen levels
8]. In contrast to rats, however, low estrogen levels in humans
re associated with cognitive decline [37].
Not only chemotherapy is associated with cognitive decline.
ther adjuvant treatments for cancer, such as radiation, are also
C
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ssociated with similar long-term effects. Raber et al. found that
57BL/J6 mice showed hippocampal-dependent spatial learn-
ng and memory impairments in the Barnes maze, but not in the
WM task 3 months after localized radiation to the bilateral
ippocampus and cortex [31]. Rola et al. found a similar effect
fter whole brain radiation in C57BL/J6 mice, but here a spa-
ial memory retention deficit was seen in the MWM task [32].
omparable effects after radiation were seen in rats. For exam-
le, Madsen et al. found that Wister rats performed worse in
n object recognition task, but performed well in the MWM
ask after multiple radiation treatments directed at the hip-
ocampal area [28]. Yoneoka et al. showed that Fisher rats
erformed well in the MWM task and the passive avoidance
ask 6 and 9 months after multiple treatments with fractioned
hole brain radiation, but worse in the same task 12 months after
reatment [47].
In the current study, the observed decline in cell proliferation
een in the animals after treatment with MTX might not be the
ain or sole explanation for the observed cognitive impairment
een in patients after treatment with chemotherapy. Ahles and
aykin describe several potential mechanisms for this cognitive
mpairment, which could also contribute to the decrease in cell
roliferation; these mechanisms include DNA damage, oxida-
ive stress, encephalopathy, cytokine activation, telomere length
nd telomerase activity, neurotransmitter activity, and neuronal
epair [2].
We want to emphasize that in our study, MTX was used as
n animal model for adjuvant chemotherapy given to breast
ancer patients. However, this does not mean that all cyto-
tatics will produce the same effects on cell proliferation or
ehavior. In order to validate our animal model, we will test
ther cytostatics in a future study. Furthermore, it seems that
he learning task and the time after treatment are crucial for
nding a correlation between the decrease in hippocampal
ell proliferation after cytostatics and the effect on cognitive
ehavior.
In conclusion, it can be said that MTX affects hippocam-
al cell proliferation in a dose-dependent fashion. This lasting
ecrease in hippocampal cell proliferation might be responsible
or the negative effect seen in spatial and comparator memory
fter treatment with MTX.
It is expected that in 2015 the incidence of breast cancer will
e around 17,000 in The Netherlands alone [41], and that in half
f these patients chemotherapy will be part of the treatment
trategy. Therefore, it is important to systematically investi-
ate the underlying mechanisms of any potential late effect of
hemotherapy that can seriously affect the quality of life of these
atients. This may help elucidate the mechanisms that underlie
he cognitive deficits found in a number of breast cancer patients
reated with adjuvant chemotherapy.
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